External broker reports(aggregated public sources), Topline Securities

Topline Securities

Topline Securities is one of the fastest growing brokerage houses in Pakistan. It has strong equity brokerage, economic / equity research, mutual fund distribution, commodity trading and corporate finance & advisory functions. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>Searle company limited (SEARL) conducted its Corporate Briefing Session today where management discussed financial performance and outlook.</li><li>Company's revenue CAGR remained at 17% over the last five years. In 1QFY26, company revenue growth remained at 28% YoY and company is targeting growth of ~23% on volumetric growth and slightly lower than 40% in value terms.</li><li>The company's top five brands include Extor, which generates revenue of Rs4.5bn; Nuberol, Rs4bn; Hydryllin, Rs3bn and Tramal and Peditral, each with revenue exceeding Rs1bn.</li></ul>

Searle company limited (SEARL) conducted its Corporate Briefing Session today where management discussed financial performance and outlook.Company's revenue CAGR remained at 17% over the last five years. In 1QFY26, company revenue growth remained at 28% YoY and company is targeting growth of ~23% on volumetric growth and slightly lower than 40% in value terms.The company's top five brands include Extor, which generates revenue of Rs4.5bn; Nuberol, Rs4bn; Hydryllin, Rs3bn and Tramal and Peditral, each with revenue exceeding Rs1bn.

Topline Flash Note: The Searle Company (SEARL): Corporate Briefing Key Takeaways